Filter by Category: In Vitro Activity

Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design

Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design, Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU

Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU, Lead author: Jones RN, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA

Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3263-3270

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species.

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. by Pfaller MA, Rhomberg PR, Messer SA and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 259-263

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013).

Update on the linezolid in vitro activity through the Zyvox® Annual Appraisal of Potency and Spectrum Program (2013). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2015; 59 (4): 2454-2457

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.

Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 275-279

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. by Jones RN, Turnidge JD, Moeck G, Arhin FF and Mendes RE published in Antimicrob. Agents Chemother. 2015; 59 (4): 2405-2409,

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas.

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629